The rates were significantly lower for the entecavir group vs the lamivudine group for HBV-related hepatitis ( @ % vs @ % , respectively ; difference between groups , @ % -LSB- @ % CI , @ % to @ % -RSB- ; P = @ ) , HBV reactivation ( @ % vs @ % ; difference , @ % -LSB- @ % CI , @ % to @ % -RSB- ; P = @ ) , and chemotherapy disruption ( @ % vs @ % ; difference , @ % -LSB- @ % CI , @ % to @ % -RSB- ; P = @ ) .